Method of treating inflammations of anterior eye segment

FIELD: medicine.

SUBSTANCE: physiotherapeutic goggle device BLEPHASTEAM is placed over an orbital cavity. Restasis is applied on cotton pads in the amount of 4 drops equally spaced over each cotton pad. The pads are placed into the device. The physiotherapeutic exposure covers open eyelids for 10 minutes daily. The therapeutic course consists of 20 sessions.

EFFECT: method provides a pronounced anti-inflammatory, reparative, anti-allergic effect with reducing the length of treatment and ensuring cost advantages of using the expensive drug Restasis evaporated in the goggle BLEPHASTEAM, allowing for the simultaneous effect on the cornea, conjunctiva and eyelids.

8 dwg, 2 ex

 

The present invention relates to ophthalmology and is designed to optimize the treatment of patients with inflammatory conditions of the anterior segment of the eye (severe corneal xerosis and blepharoconjunctivitis, including in combination with polyvalent Allergy to the medicine, as well as ophthalmopathy) a combination of restasis and physiotherapeutic method for using the device BLEPHASTEAM. These diseases are characterized, in particular, lymphocytic infiltration and autoimmune manifestations and development of dry eye syndrome.

Autoimmune processes take place in dry eye syndrome (DES), associated with Sjogren syndrome. The role of inflammation in the pathogenesis of SHBG is crucial for understanding the development of different symptoms. Lymphocytic infiltration of target organs, in particular the lacrimal gland, activated CD4 T - and b-cells, leads to an increase in the concentration of soluble Pro-inflammatory cytokines: IL-1 β, IL-2, interferon - γ tumor necrosis factor - α and other inflammatory mediators. Dysfunction of the lacrimal gland due to the development of autoimmune dacryoadenitis leads to changes in the structure and stability of the tear film and, consequently, to the defeat of the cornea, conjunctiva and goblet cells, which clinically manifests corneal conjunctiva is determined as being developing. The largest number of patients with corneal conjunctival developing with sjögren's syndrome is observed chronic eyelid defects in the form of posterior blepharitis. The clinical picture of the rear of blepharitis is characterized by dysfunction marojevic glands, violation of the integrity of the lipid layer of the tear film, inflammation, and neovascularization of the edges of the eyelids.

Strategy the treatment of corneal conjunctival xerosis, along with the permanent instillation of substitutes, installing plugs to preserve residual secretion, is the use of anti-inflammatory drugs that suppress the process lymphocytic infiltration, glucocorticoids and immunosuppressants (Me Cully J.P., Shine W.E. Changing concepts in the diagnosis and management of blepharitis. Cornea 2000: 19; p.650-658. G.N. Fouks. The evolving treatment of dry eye. Ophthamology Clinics of North America 2003: v.l6. N1, p.29-35). However, this therapy is limited in cases of severe and very severe xerosis - ulceration of the cornea.

Traditional therapy posterior blepharitis involves performing hygiene century, instillation of antibiotics and glucocorticoids, as well as the course of antibiotics inside (tetracycline, doxycycline). (M.J. Quarteman, D.W. Johnson, D.C. Abele, I.L. Lester Jr, D.S. Hull, L.S. Davis Ocular rosacea: signs, symptoms, and tear studies before and after treatment with doxycycline. Archives of Dermatology 1997. V.133, N 1, p.49-54. Cheung J, Sharma S. Ophthaproblem. Blepharitis. Can. Fam. Physician 2000; 46; p.2393-2400. M. Calonge. The treatment of dry eye. Surve of Ophthalmology. 2001; v.45 suppl.2; p.S227-239).

In the treatment of inflammatory conditions of the anterior segment of the eye uses a combination of various treatment methods and medicines. There is a method of treatment of keratitis various etiologies, especially with the expressed pain syndrome, using electrophoresis with zinc sulfate, sulfacetamide or antibiotics. It should be noted that the medicinal substance is injected in small amounts (usually in milligrams) and due to ion-dissociated form retains its pharmacological activity. This is followed by a longer duration of action of the medicinal product and the slow excretion. As a rule, during electrophoresis there are no adverse reactions peculiar medicinal substances used in traditional ways of introduction. Intake of drugs is painless, no deformation fabrics (Polunin G.S., Makarov I.A. /Physiotherapeutic methods in ophthalmology.// Moscow, publishing house of Medical information Agency, 2012, p.21,22).

A positive therapeutic effect is observed with the use of ultrasound for the treatment of conjunctivitis and blepharitis of meibomitis, dry eye syndrome, keratitis. Ultrasound has on tissues and organs is a complex effect, resulting from thermal, mechanical, chemical and electrical is fiziologicheskii. One of its characteristic properties is "razvratnayaa" the action in the treatment of diseases involving productive inflammation and regeneration, promotes less rough to the formation of scar tissue. When the subsidence of the inflammatory process ultrasound also provides a resolving effect on the consequences of exudate and fibrosis, which allows very efficient to use in inflammatory diseases beyond the acute stage. The influence of ultrasound accompanied analgesic effect. The aggregate responses to the application of ultrasound include local tissue reaction, followed by activation of enzyme, trophic regenerative processes of microcirculation, as well as complex neurohumoral reactions associated with the stimulation of adaptive and protective mechanisms that increase non-specific resistance of the organism (Polunin G.S., Makarov I.A. /Physiotherapeutic methods in ophthalmology.// Moscow, publishing house of Medical information Agency, 2012, pp.92, 94,99).

To ensure blepharoconjunctivitis forms of dry eye syndrome is widely used phonophoresis using as a contact environment leverages-1 or -2 (Polunin G.S., Makarov I.A. /Physiotherapeutic methods in ophthalmology.// Moscow, publishing house of Medical information and andtwo, 2012, p.100.) Blearily 1 and 2 can be used to treat blepharoconjunctivitis forms of dry eye syndrome without additional combination with ultrasound and other physiotherapeutic methods (EN 2312640, 20.12.2007).

There is a method of treatment of blepharoconjunctivitis caused by Demodex mites by instillation trophic drops with further physiotherapy by pulsed radiation with a wavelength of 800-1200 nm, continuous radiation with a wavelength of 630-670 nm, and the magnetic field intensity H=20-45 MT on the eyelids and adjacent to the eye area. The use of radiation of the electromagnetic field reduces the treatment time and increases efficiency by suppressing the activity of the tick (EN 2440803, 2012). This method is used only in the treatment demodecosis forms of blepharoconjunctivitis, which limits its use in the clinic for other inflammatory conditions of the anterior segment of the eye.

The closest analogue of the present invention is a method of treating blepharitis, keratitis (after epithelization of the cornea), conjunctivitis and endocrine ophthalmopathy by electrophoresis. The advantage of the medicinal electrophoresis is that it allows you to create a higher concentration of drugs directly into the pathological focus, in contrast, injection of the JV is to get their introduction. In the eye tissues during electrophoresis, the concentration of substances in 4-20 times higher than after their introduction in other ways. When you type the substance does not have systemic effects on the body, but only a reflex, humoral and local. The substance is introduced in small concentrations, in other ways not giving a therapeutic effect. Combined application of physical factors potentiates their effects. However, not all medicinal substances can be entered using electrophoresis. In particular, procedures for medicinal electrophoresis recommended distilled water as a basis, it is recommended to use oil fundamentals drugs (Polunin G.S., Makarov I.A. /Physiotherapeutic methods in ophthalmology.// Moscow, publishing house of Medical information Agency, 2012, p.20, 21, 22, 25, 36, 146, 156, 158, 170).

At the same time, there is a method of treating inflammatory manifestations of anterior segment of eye with use of the drug cyclosporine. For the first time in 1989 Kaswan with co-authors in a series of experimental works reproduced in dogs model dry keratoconjunctivitis showed a positive effect of local use of a solution of cyclosporine, which was shown by the regression of corneal neovascularization and granulation, decrease signs of inflammation (hyperemia of the conjunctiva) in experimental animal is H. Increased level of lesoproduktsii (according to Schirmer test), the improvement of the front surface of the eye (Kaswan R.L., M.A. Salisbury Wrd D.A. Spontaneous cnine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca: treaaatment with cyclosporine eye dropds. Arch. Ophthalmol. 107; 1210-1216, 1989).

Cyclosporin a (cyclosporine) is a cyclic polypeptide that is produced as a metabolite by the fungus Tolypocldium inflatum gams. Cyclosporine has immunomodulatory properties, inhibiting the activity of transcription factors in the nucleus of activated T-lymphocytes, inhibiting the induction of cytokines and genes required for the immune response (Kunert for K.S., TISDALE a.s., Stern M.E. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: Effect of on conjunctival; lymphocytes. Arch. Ophthalmol. 118: 1489-1496, 2000; Turner K, S.C. Pflugfelder, Ji Z. Interleukin06 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea 19: 492-496, 2000). The high incidence of side effects and lack of absorption by the tissues of the eye with the use of Cyclosporine And inside (the drug Sandimmune"), as well as the high cost was the impetus for the development of local ocular dosage forms cyclosporine, do not have a systemic effect. However, the developed tools are not received clinical distribution, because not gone beyond the experimental studies, mainly because of the "perestroika" of the domestic pharmaceutical industry (Michuk DO Judge the pilot biomedical evaluation and development of methods of application of lysosomal eye drops cyclosporine: author. dis. Kida. the honey. Sciences. - M., 1997. - 24 S.).

For use in ophthalmic practice in 2002 the company Allergan (Allergan) was developed restasis (Restasis), representing a 0.05% ophthalmic emulsion of cyclosporine A. the Drug has an osmolarity 230-320 mosmol/kg, a pH in the range of 6.5-8.0 and the inactive ingredients: glycerin, castor oil, Polysorbate 80, carbomer 1342, sodium hydroskin and purified water. Recommended double instillation of the drug, which corresponds to a daily dose of cyclosporine - 0,057 mg (Saii K, Stevenson O.D., Mundorf BECAUSE Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to evere dry eye disease. CsA Phase 3 Study Group // Ophthalmology. - 2000. - Vol.1078. - P.631-639). The mechanism of action of Restasis based, on the one hand, on the inhibition of the activation of T-lymphocytes in the conjunctiva and, on the other hand, impede the migration of new cells in the conjunctiva. On the background of the instillation of the drug marked increase in the density of goblet cells in the bulbar conjunctiva. (Pflugfelder, S.C., C.S. De Paiva, Villarreal A.L. Effect of sequential artificial tear and cyclosporine emulsion therapy on conjunctival goblet cell density and transforming growth factor-beta 2 production. // Cornea. - 2008. - Vol.27. - P.64-69).

Achieving a therapeutic effect in the treatment of posterior blepharitis to 12 weeks from the beginning of the topical application of 0.05% cyclosporine is indicated in the work of M. Rubin (Rubin M, Rao S.N. Efficacy of Topical Cyclosporin a 0.05% in the Treatment of Posterior Blepharitis. J. Of ocular Pharmacology and Therapeutics. V 22, N 1, 2006 p.47-53). PR is the comparison of two matched for age and clinical manifestations of the groups, the authors have obtained statistically reliable data on the preferential increase Schirmer test and sample burrowing in the group of patients treated with instillation of cyclosporine for 12 weeks. It should be emphasized that therapeutic effect began to occur to 8-10 weeks of treatment.

Indications for use restasis - reducing lesoproduktsii due to the dry keratoconjunctivitis. Recommended mode instillation in the conjunctival cavity of the drug twice a day. It corresponds to a daily dose of cyclosporine 0.057 mg (Sall K., Stevenson .D., Mundorf AS et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group // Ophthalmology. - 2000. - Vol.l07. - P.631-639.). When this emulsion contained in one bottle for individual use, should be used immediately after opening the bottle - the remaining amount of the drug after backfilling shall be disposed of immediately after use, which significantly increases the cost of treatment, because the drug is very high.

Among the modern methods of treatment of dry eye syndrome in clinical practice abroad implemented method of therapeutic treatment, combining thermal and moisture effects on the ocular surface and eyelids using a specially designed device in the form of points closely adjacent to the face - BLEPHASTEAM (1, 2) (Blephasteam Laboratoires THEA, FRANCE, 2009). Application BLEPHASTEAM allows you to get moisturizing and warming e is the effects. This dual action eliminates clogging marojevic glands, increases the secretion of lipids, which helps to improve the quality and stability of the tear film, superior vision, leading to improved quality of life of the patient.

The treatment will consist in the following: produce wetting paper liners for BLEPHASTEAM mineral water or a solution containing salt. When connecting the rim to the electrical network begins heated liners. Moisture from the paper liners-rings under the influence of heat evaporates, the effect of a "steam bath" and microclimate over the ocular surface and eyelids. These procedures are performed with the eyes open. The use of a spectacle frame BLEPHASTEAM known only in the treatment of dry eye syndrome.

Disclosure of inventions

The objective of the invention is to develop a new combined method for the treatment of inflammatory conditions of the anterior segment of the eye.

The technical result of the proposed method is a pronounced anti-inflammatory, reparative, anti-allergic effect in the reduction of treatment time, as well as the economic effect of the use of expensive drug Restasis.

The technical result is achieved due to the use of restasis in his summing up to the front treskovaja device BLEPHASTEAM.

In the proposed method is a combination of medicinal and therapeutic effects, and, in essence, a new way of deciding on restasis for anterior segment of the eye.

Known contraindications to the use of a spectacle frame BLEPHASTEAM are, in particular, acute inflammatory diseases of the eye and eyelids. In our proposed method, this device can be used in conjunction with the restasis, which has anti-inflammatory effect, which allows you to apply BLEPHASTEAM and inflammation of the anterior segment of the eye blepharitis, keratoconjunctivitis and endocrine ophthalmopathy.

The restasis contains among other components of castor oil, which upon instillation in the conjunctival cavity has a local irritant effect. In addition, this drug cannot be recommended to sum to the front segment of the eye and by electrophoresis as to improve absorption of cyclosporine A. In its composition included polyoxyethylene ether of castor oil. However, it is known that medicinal electrophoresis (iontophoresis) use water-soluble medicinal substance capable of electrical dissociation on the corresponding ions moving under the action of electric current from one pole to the other.

The advantage of the proposed method before electrophoresis is that you do not need to enter a tampon or more medicinal substance into the conjunctival cavity with the defeat of the cornea, as is done in the electrophoresis, which allows to simplify the treatment procedure. In addition, the eyeglass frame BLEPHASTEAM easy to use and does not require the presence of a physician during its use, unlike all types of electrophoresis.

Evaporation of medicinal substance in a spectacle frame BLEPHASTEAM simultaneously effectively influence the cornea, conjunctiva and eyelids, while maintaining all the advantages of electrophoresis: local, painless impacts, while achieving long-term therapeutic effect.

Under our supervision there were 10 patients (20 eyes) aged 60-82 years; with various inflammatory conditions of the anterior segment of the eye:

late stage of corneal conjunctival xerosis - filamentous keratitis, chronic blepharitis, endocrine ophthalmopathy. The criterion for selection of patients for treatment was prolonged absence (not less than 1 year) therapeutic effect of the application of various types of therapy (substitutes, ceratopetalum, necrotic means). Visual acuity in these patients prior to treatment is not offset the La 0.2 and not korrelirovalisj. Indicators Schirmer test (without anesthesia) was 5-6 mm for 5 minutes, samples burrowing - 3-4 C.

The clinical picture was characterized by:

- redness of the eyelid margins,

the presence of newly formed vessels in the intercostal region,

- stenosis mouths outlet duct marojevic glands

- pronounced injection and swelling of the conjunctiva of the eyelids and transitional folds, "sluggish" hyperemia of the bulbar conjunctiva,

- presence of mucous discharge in the form of threads in the cavity of the conjunctiva,

- two-way epitheliopathy of the cornea (corneal surface) with the presence of epithelial threads on its surface.

After a course of treatments using the spectacle frame BLEPHASTEAM in combination with restasis with biomicroscopy noted: mild signs of inflammation - the disappearance of redness and swelling of the edges of the eyelids and the conjunctiva of the eyelids, the narrowing of the caliber ("zapustevanie") of newly formed vessels in the intercostal region of the eyelids, opening mouths marojevic glands, no slimy filamentous discharge within the cavity of the conjunctiva, a significant reduction of the area of epitheliopathy of the cornea (or complete lack thereof), increases the width of the palpebral fissure, reducing photophobia.

During the first session using a spectacle frame BLEPHASTEAM in combination with restasis patients did not report discomfort. the nor sensed humidity, heat and saw a slight film - suspension of the drug. Immediately after the first session, patients noted significant improvement, reflected in the fact that they for the first time in a long time, should not have been surety eyes, and could open them and blinking, without discomfort (effect after the first treatment lasted about 6 hours).

After the second session the effect lasted for a day; if biomicroscopy showed a significant reduction of inflammation in the eyelids, reducing the number of " threads" on the cornea. After 3 sessions were increasing positive dynamics in terms of the reduction of redness, swelling, increase Schirmer test and sample burrowing (Fig 3, 4). After 8 session visual acuity in both eyes of patients increased (1-5 lines each eye) or did not change. After 20 sessions, the visual acuity of patients in both eyes increased in 9 patients. After the end of treatment remission lasted for at least 3 months.

In our proposed method, the drug Restasis is used more sparingly than when backfilling, because 1 ring-liner in points (1 eye) put 4 drops of the drug (half a vial), so 1 session (1 day) in both eyes using the full vial course (20 days) spend up to 20 vials; whereas instillation of the drug Restasis drops use 1 drop in the den is in each eye every 12 hours. Remaining after opening of the ampoule the drug is disposed of, as it cannot be stored. Thus, for night use 2 capsules, half the contents of which have to be disposed of. In the course of treatment (6 months) with this method of introduction of restasis spend 180 vials of the drug.

The method is as follows.

Frame of spectacles BLEPHASTEAM heated in accordance with the instruction for 20 minutes at a voltage of 110 or 220 C.

Then on the cotton ring cause restasis 4 drops to 1 ring at the same distance from each other. Q-rings are placed in the frames of the glasses BLEPHASTEAM, then put on a spectacle frame BLEPHASTEAM patient with open eyes for 10 minutes. Showtimes are 1 times a day for 20 days.

Clinical example 1.

Patient S., aged 63. Diagnosis: OU - keratoconjunctivitis sicca (filamentous keratitis of both eyes), hyponatremia III degree. Complaints: OU - photophobia, discomfort, cramps and pain in the eyes, burning sensation and sand in the eyes, separated in the form of threads, blurred vision within 10 years. The patient polyvalent Allergy medicines. Biomicroscopic picture was characterized by: OU photophobia, narrowing of the palpebral fissure to 5 mm on both sides, redness of eyelid margins, the presence of newly formed vessels in the intercostal region, stenosis of the mouths of the outlet duct is abayevich glands sections "baldness"; expressed injection and swelling of the conjunctiva of the eyelids and transitional folds, presence of mucous discharge in the form of threads in the cavity of the conjunctiva, two-way epitheliopathy of the cornea with the presence of epithelial threads on its surface (the clinical picture is more pronounced on the left) (Fig 3. Left eye before treatment. Filamentous keratitis). Visual acuity OD=0.8 n/a, OS=0.3 sph-2.0=0.7-0.8. Indicators Norn tests: OU 8 S., Schirmer test: total tear production: OD=13, OS=14; reflex: OU=5.

Completed the treatment of the 20 procedures 1 time per day. The patient endured the procedure well and with 8 session eliminated the need for the use of tear replacement therapy.

After the treatment, the patient no complaints. When biomicroscopy: OU: photophobia is missing, the width of the palpebral fissure has almost doubled in both eyes, ciliary eyelids are pink, pure. The newly formed vessels in the intercostal region age "zapustili". OD: the mouth of the outlet duct marojevic glands revealed. OS/eyelid - mouth marojevic glands disclosed, are determined in succession, on the lower eyelid, there are small areas of "baldness". All 3 of the Department of the conjunctiva without pathological changes, the cornea is a transparent, high-gloss, the epithelium is restored (Figure 4. Left eye after treatment. Full recovery of the corneal epithelium (no procrasti is the W of the corneal epithelium 0.1% solution of fluorescein). Visual acuity OD=1.0 n/ a OS=0.4 sph-2.0=1.0. The Schirmer test: total tear production OD=20, OS=15, reflex: OD=7, OS=5. Sample burrowing OU=1

Clinical example 2. The Century patient, 68 years of age. Diagnosis: OU - blepharoconjunctivitis form of dry eye syndrome, primary cataract. Complaints: OU: Itching of the eyelids, discomfort, pain and burning in the eyes, periodically mucous discharge in the morning, blurred vision within 5 years. Allergies to medicines not.

Biomicroscopic picture: OU "crust" on the eyelashes, redness and swelling of the eyelid margins ciliated, stagnation marojevic glands expressed injection, conjunctival hyperemia century and transitional folds, the presence of scanty mucous discharge in the cavity of the conjunctiva, cornea without pathology, are included in the tear film. (Figure 5. Redness eyelid margins before treatment), (6. The edge of the lower eyelid to a course of treatment. The mouth of the excretory ducts marojevic glands not contribute ("patches of alopecia")).

Visual acuity OU sph-1.5=1.0. Indicators Norn tests: OU 12 S., Schirmer test: total tear production: OD=4, OS=3; reflex: OD=7, OS=5 mm Carried out the treatment of the 20 procedures 1 time per day. The patient endured the procedure well. After the 5th session stopped using tear replacement therapy. Follow-up appointments after treatment. No complaints. When biomicroscopy: OU: "Crusts" on ciliary the Rai no age, hyperemia, edema of the eyelid margins ciliated and stagnation marojevic glands. All 3 of the Department of the conjunctiva without pathology, the cornea is a transparent, high-gloss. Inclusions in the tear film and detachable no (Fig.7. The state of the ciliary edge of the lower eyelid after a course of treatment. Contribute mouth marojevic glands), (Fig. Increasing the height of the tear stream after treatment). Visual acuity OU sph-1.5=1.0 Schirmer Test: total tear production OU=25, reflex OU=10 mm Sample burrowing OU=15 C.

Thus, the method allows to achieve a combined anti-inflammatory, reparative, anti-allergic effect when exposed to the eyelids and ocular surface, to reduce the treatment time, to expand the indications for treatment and to optimize the consumption of the drug Restasis inflammation of the anterior segment of the eye.

A method of treating inflammatory conditions of the anterior segment of the eye, characterized in that the area of the orbit is placed physiotherapy eyeglass device BLEPHASTEAM, and pre-4 drops restasis put at the same distance from each other on the cotton rings, place them in the device and conduct a physical impact with open eyelids for 10 minutes daily, at the rate of 20 sessions.



 

Same patents:

Information glasses // 2452988

FIELD: physics.

SUBSTANCE: information glasses have an electronic control circuit, a rim with two ear hooks and two eyepieces, for each of which a reflecting mirror is placed directly at the break point of a broken optical axis. According to the invention, the information glasses have for each of the two ear hooks an electro-contact drum, having a set of several electro-contact discs insulated from each other, wherein the longitudinal axes of the electro-contact drums are simultaneously the axes of rotation of the ear hooks of the information glasses, which also have for each of the two eyepieces an information optical system, for which a colour graphic display is placed along the top edge of the eyepiece of the information glasses at the initial section of the broken optical axis, and the reflecting mirror is placed along the bottom edge of the eyepiece of the information glasses, wherein the longitudinal geometric axes of the colour graphic display and the reflecting mirror are parallel to each other.

EFFECT: ensuring rapid display of text and symbolic information in running letters mode on the screen of the colour graphic display of the information glasses.

7 cl, 4 dwg

FIELD: medicine; ophthalmology.

SUBSTANCE: bidirectional-prism spheroprismatic lenses comprise a prism with a horizontally-directed base and a prism with a vertically-directed basis. Strength of the second vertically-directed prism differs upward from that of the first horizontally-directed prism.

EFFECT: unloading of eye muscle at short-distance work related to down-looking.

5 dwg

FIELD: medical engineering.

SUBSTANCE: device has eyepieces having viewing opening. The eyepieces are manufactured from tinted transparent material. Distance between the viewing openings in the eyepieces is equal to interpupillary distance of given patient. Viewing opening diameter is 0.5-3.0 mm large.

EFFECT: reduced fatigue of eye-moving apparatus; created conditions for saccade automation.

2 cl, 1 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves adjusting spherical and cylindrical correction components. Vertex distance and inclination angle of ear-back part to spectacle rim are determined in available glasses. Heterophoria and anisometropia availability is determined. Vertex distance being greater than 12 mm and/or inclination angle of ear-back part to spectacle rim being greater than 87° or less than 80°, vertex distance is changed to 12 mm and inclination angle to 87° - 80°. Heterophoria being found greater than 10 diopters, additional prismatic correction members are introduced to compensate heterophoria at least to one half. Anisometropia being available, spherical and/or cylindrical correction components are reduced on the eye having less ametropia degree.

EFFECT: improved comfort conditions in carrying glasses.

FIELD: medicine; optical instruments for taking preventive measures and curing eye diseases.

SUBSTANCE: goggles for preventive treatment for acquired short sight have spherical-prismatic lenses mounted in frame of goggles. Edge of one lens turned to nose support is disposed at angle α1=180° +-90° up or down from horizontal axis and edge of other lens turned to nose support is disposed at angle α2=0°+-90° up or down from horizontal axis. In this case vertex-base lines of prisms are parallel to each other; bases of prisms are disposed at internal quadrants and lenses themselves are disposed in universal frame for rotation around optical axis with pitch of 0-15° between meridians. Degree of relaxation of ciliary muscle is improved.

EFFECT: improved efficiency of treatment; higher level of adaptability of oculomotoris muscle.

2 cl, 1 dwg, 1 ex

Perforation glasses // 2253143

FIELD: ophthalmology.

SUBSTANCE: perforation glasses have behind-the-ears holders made of linear rods which curve inside and ophthalmologic frame. Non-transparent discs with holed rasters are fastened to the frame. Holes of raster have round conic shape; bigger base of cone is directed to eye to provide getting interference pattern in form of alternating dark and light rings placed along the whole cross-section of light beams which pass those holes through. Holes are located in center hexagonally and have distances among centers to provide overlapping of interference fields with rings belonging to the same type - dark or light - to cover less than half of the surface at all the directions. Holes in rasters have different diameters in vertical rows and any nontransparent disc has lack of segments on the bottom or on the top. Increase in diameters of holes in rasters in vertical rows is performed in the direct their spatial orientation of absent segments. Nontransparent discs are connected to ophthalmologic frame non depending on each other by means of two movable spherical hinges to provide ability of changing their spatial orientation. Rods of behind-the-ears holders have lengths providing overlapping of their ends. One of the ends has massager with two-sided thorns disposed on both sides of behind-the-ear holder. The second behind-the-ear holder has corresponding holes corresponding to sizes and location of thorns on the first behind-the-ear holder. There are longitudinal grooves at straight parts of behind-the-ear holder. Movable permanent magnets and massaging members with thorns are mounted inside those longitudinal grooves.

EFFECT: improved reliability; improved efficiency; widened area of application.

8 dwg

FIELD: ophthalmology; medical engineering.

SUBSTANCE: lens glasses have two systems consisting of lens and eye-piece, both disposed in two tubes correspondingly, device for automatic adjustment of focal length of lens by means of control and adjustment unit which has lens positioning mechanism and eye-piece and is connected with unit for automatic matching of angle between optical axes of glasses having corresponding focal length to provide passage of optical axes of glasses through optical centers of user's eyes at any position of tubes. Control and adjustment unit has device for changing magnification factor and provides calculation of required angle between optical axes at active working distance, position of lenses in eye-pieces and lenses and device for inspecting lens and eye-piece positioning mechanism. Device for changing magnification factor is connected with foot switch. Change in magnification factor is performed smoothly. Device for automatic adjustment of focal length of lens is made for selection of switching on or off. Glasses are provided additionally with aid for changing focal length and magnification factor upon getting voice command from user. Glasses are also provided with measuring scale matched with corresponding magnification factor. The scale illuminates in focal plane for precised measurement of sizes of object.

EFFECT: improved comfort at operation.

5 cl, 3 dwg

The invention relates to the field of optics, in particular to devices for vision correction

The invention relates to the design of the glasses used for sports, namely swimming, Cycling, etc

The invention relates to playback of the video data into a three dimensional form, namely television, and is intended for monitoring of stereo images with screen color TVs, monitors, displays, computers and t

FIELD: medicine.

SUBSTANCE: treating retinal and/or vitreous hemorrhages is ensured by a session of subcutaneous administration of Histochrom 0.5 ml into a mastoid bone, Echinacea compositum 1.0 ml into a temporal fossa, Gemase 2500-5000 IU parabulbary dissolved in Lymphomyosot 0.5-1.0 ml. The therapeutic course is 10-15 sessions, either daily or every second day.

EFFECT: faster resolution of the intraocular hemorrhages, prevention of retinal injuries by toxic decay products, higher visual acuity.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to ophthalmology, to preparations for the treatment and prevention of eye diseases, and may be used in visual impairment, development and progression of eye diseases, as well as for the prevention and maintenance therapy of oxular diseases. Substance of the invention consists in the fact that a therapeutic eye balsam is characterised by the fact that it contains the ingredients in ratio in grams per 100 g of the therapeutic eye balsam of the following formulation: Siberian fir extract - 48.540 g, 5% propolis extract - 10.000 g, 0.9% physiological saline - 38.540 g, neoselen (food supplement) - 0.971 g, vitamin B2 - 0.007 g, citric acid - 0.971 g, ascorbic acid - 0.971 g that promotes achieving the declared technical effect ensured by the given proportions. The presented balsam enables the higher clinical effectiveness in all the forms of ocular pathologies, provides the anti-inflammatory effect on the eye mucosa and cornea, as well as delivers a good result in the post-traumatic and post-operative treatment.

EFFECT: therapeutic eye balsam containing the natural ingredients in certain proportions provides the integrated therapeutic effect on the visual organs and has found use in a great number of grateful patients.

1 cl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a pharmaceutical composition and methods of using it in treating insufficient eye lubrication, related symptoms or adverse conditions related to insufficient eye lubrication. The pharmaceutical composition contains human PRG4, its wetting fragment, a homologue or an isoform suspended in ophthalmologically acceptable balanced saline. The pharmaceutical composition can also contain one or more ophthalmologically acceptable agents specified in a group consisting of a sedative, an excipient, a binding agent, a vasoconstrictor, an emollient, sodium hyaluronate, hyaluronic acid and surface active phospholipids in a pharmaceutically acceptable carrier for topical use.

EFFECT: group of inventions provides treating the diseases related to impaired corneal and conjunctival wetting.

15 cl, 10 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: what is presented is a method for the suppression of physiological disorders related to abnormal angiogenesis, specified in retinopathy, diabetic retinopathy, macular degeneration, retinopathy of prematurity, age-related macular degeneration, pancreatic tumour and glioma, involving the administration of an effective amount of 3-[(5-(2,3-dimethoxy-6-methyl-1,4-benzoquinolinyl)]-2-nonyl-2-propenoic acid (E3330) or its pharmaceutically acceptable salts or solvates. The decreased EHF-1α, NFKβ, AP-1 activity by E3330 and the suppression thereby of the growth, survival. Migration and metastasis of tumour cells are accompanied by the absence of the major suppression of the growth of normal cells (hemopoietic embyo cells or CD34+ human progenitors). Besides, E3330 has enhanced the therapeutic effect of other cytotoxic preparations.

EFFECT: reducing the amount of VGEF and proliferation of retinal endothelial cells by E333O even in the presence of a fibroblast growth factor, both in the normal oxygen conditions, and in the hypoxia by the inhibition of the oxidation-reduction activity of Apel/Ref-1.

12 cl, 35 dwg

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to eye drops, and aims at treating dry eye syndrome, as well as bacterial conjunctivitis and/or blepharitis. The preparation comprises a combination of the ingredients, a prolonging ingredient, additives and water. The combination of the active ingredients contains branched polyhexamethylene guanidine and sulphacetamide; the prolonging ingredient is specified in a group consisting of polyvinyl alcohol, water-soluble methyl cellulose or hydroxypropyl methyl cellulose; the additives are specified in a group consisting of a group consisting of physiologically acceptable alkaline or acid agents, and a saline tonic agent.

EFFECT: using the invention enables higher clinical effectiveness of dry eye syndrome, as well as a comorbid bacterial infection, as the preparation possesses the bactericidal effect consistent with the effect of 20% sulphacetamide causing no irritant effect on long use.

4 cl, 3 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely ophthalmology. The method involves a transepithelial corneal collagen crosslinking. That is preceded with a single bath electrophoresis with 1% riboflavin mononucleotide. That is ensured by an initial current of 0.2 mA to be increased gradually to 1 mA, at a pitch of 0.2 mA for 2 minutes. That is followed by an ultraviolet corneal exposure. The exposure is conducted at wave length 370 nm, power 3 mWt/cm2 and combined with instillation of a riboflavin solution. The solution contains 0.1% riboflavin mononucleotide and 20% dextran.

EFFECT: method provides more effective riboflavin delivery to the corneal stroma for one procedure providing the intraocular protection against ultraviolet light.

2 cl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, ophthalmology. A method involves a sinus trabeculectomy, a local sclerectomy and a drug delivery to a posterior pole of eyeball following by a restorative treatment. The local sclerectomy is performed in an inferior-internal segment of the eye with a cross-section of the incision being semi-circular. The local sclerectomy uses Histochrom as a drug substance. The restorative treatment comprises subconjunctival drug injections in a combination with the exposure to a physical factor. Starting from the first postoperative day, Histochrom is injected into a sub-Tenon's space. There are 9 injections performed once a day. Starting from the second postoperative day, a magnetic stimulation is used at frequency 100 Hz, length 16 minutes once a day for 7-10 days. The first 3 sessions involve the exposure to a pulsating monopolar magnetic field of intensity 6.25 mT. The following 4-7 sessions involve the exposure to an alternating bipolar magnetic field of intensity 12.5 mT.

EFFECT: method provides stabilising and enhancing the visual functions.

5 cl, 1 dwg, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to ophthalmic preparations presented in the form of eye drops and applicable for treating dry eye syndrome and bacterial conjunctivitis. The preparation contains polyhexamethylene guanidine that is presented by branched oligomers in the form of hydrochloride; besides, phosphate buffered saline, poly(N-vinylpyrrolidone) and water are the ingredients.

EFFECT: using the invention provides the higher clinical effectiveness in dry eye syndrome, as well as potential comorbid bacterial infection whereas the declared preparation has no irritant effect if used for a long period of time.

3 cl, 2 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly ophthalmology, and may be used for treating inflammatory and dystrophic eye diseases. If observing an anterior segment of an eyeball, therapeutic agents are administered subcutaneously into a temporal region 1.8-2.2 cm above the middle of a cheek bone into a lymphatic capillary accumulation. If observing a posterior segment of the eyeball, the therapeutic agents are administered subcutaneously 0.8-1.2 cm below the top of a mastoid bone, as well as into the lymphatic capillary accumulation. Heparin in a single dose of 0.3 to 0.6 ml with the therapeutic substance concentration of 96% to 100% is initially administered into the above regions. The basic substance solution in a single dose of 0.6 to 0.8 ml with the therapeutic substance concentration of 45% to 55% is administered thereafter. That is followed by administering Contrykal in a single dose of 0.4 to 0.6 ml with the substance concentration of 45% to 55%. The manipulations are daily for 7-10 days with the therapeutic course repeated every 1-6 months.

EFFECT: method provides better trophism and microcirculation of an optic disk and retina, lower intensity of pathological reactions with obtaining the therapeutic substance concentrations faster, reducing injuries of the manipulation and doses of the administered preparations.

FIELD: medicine.

SUBSTANCE: invention relates to medicine, particularly to ophthalmology. That is ensured by the integrated treatment involving the single macular exposure to a sublimit micro-pulse infrared laser light. That is combined with the ozone therapy using drug preparations with underlying mixed gas agitation. That is followed by an antioxidant therapy consisting of local instillations of emixipin and oral administration of complivit oftalmo.

EFFECT: method enables the therapy of predisciform age-related macular degeneration at the stage of confluent drusens, preventing the development of the disease and improving the visual acuity.

2 ex

FIELD: medicine.

SUBSTANCE: suppurative focus is exposed, drained and sanitated. That is followed by the postoperative subcutaneous administration of drug preparations on the border of middle and lower thirds of leg according to the following regimen: First Lydase dissolved in 0.25% novocaine 2 ml is administered first. After 5-10 minutes, third-generation Cephalosporin 1000 mg dissolved in 0.25% novocaine 5 ml for 5 days is administered. That is followed by administering 4 injections of derinate 5 ml every two days.

EFFECT: invention provides the lymphatic canal sanitation and the recovery of its function with reducing a quantity of recurrences and postoperative complications in the patients with paraproctitis.

1 ex

Up!